Alere Determine Rapid Test – Educational/Training Video

The Alere Determine™ HIV-1/2 Ag/Ab Combo Test is the first FDA approved single-use, rapid point-of-care, in vitro qualitative test that detects both HIV-1/2 antibodies and free HIV-1 p24 antigen in human whole blood, fingerstick blood, or plasma. This 4th generation test has the ability to identify HIV sooner than currently available conventional rapid tests, which rely solely on the presence of HIV-1/2 antibodies. It enables health care providers to diagnose HIV infection earlier allowing individuals to seek medical care sooner. Click on image below for larger view.
alere-determine-hiv1-2-p24
The test is intended for use as a point-of-care test to aid in the diagnosis of infection with HIV-1 and HIV-2, including an acute HIV-1 infection, and may distinguish acute HIV-1 infection from established HIV-1 infection when the specimen is positive for
HIV-1 p24 antigen and negative for anti-HIV-1 and anti-HIV-2 antibodies. The test is suitable for use in multi-test algorithms
designed for the statistical validation of rapid HIV test results. When multiple rapid HIV test are available, this test can be used in appropriate multi-test algorithms.

The assay is packaged as a kit containing Alere Determine™ combo cards (with 5 or 10 Test Units which can be separated from each other by tearing along the perforated lines), Chase buffer, and is available in point-of-care use packaging, or packaging suitable for laboratory use. Each Test Unit has a cover that is to be removed for sample application and visualization of test results.